Management tracks: Denali, Convert

Neurology company Denali Therapeutics Inc. (NASDAQ:DNLI) appointed Jennifer Cook to its board. She is CEO of Grail Inc. (Menlo Park, Calif.) and previously was global head of clinical operations of Roche (SIX:ROG; OTCQX:RHHBY).

Convert Pharmaceuticals S.A. (Liege, Belgium) hired Mariola Söhngen as CEO as the cancer company prepares for its lead compound, CP-506, to enter the clinic. CP-506 is a hypoxia-activated cytotoxin prodrug. Söhngen, who was CEO of Mologen AG (Xetra:MGNK), succeeds acting CEO Janwillem Naesens. ...